Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease
Abstract.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concentratio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2006-01-01
|
| Series: | Journal of Pharmacological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319345396 |
| _version_ | 1830161890542616576 |
|---|---|
| author | Akiko Nakatsuka Masahiro Nagai Hayato Yabe Noriko Nishikawa Takuo Nomura Hiroyoko Moritoyo Takashi Moritoyo Masahiro Nomoto |
| author_facet | Akiko Nakatsuka Masahiro Nagai Hayato Yabe Noriko Nishikawa Takuo Nomura Hiroyoko Moritoyo Takashi Moritoyo Masahiro Nomoto |
| author_sort | Akiko Nakatsuka |
| collection | DOAJ |
| description | Abstract.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concentration of cabergoline in healthy male volunteers and in PD patients. Study 1: Ten healthy male volunteers were enrolled and were randomized to take a single oral dose of cabergoline (1 mg/day) for 6 days or a single oral dose of cabergoline plus clarithromycin (400 mg/day) for 6 days. Study 2: Seven PD patients receiving stable cabergoline doses were enrolled. They were evaluated for the plasma cabergoline concentration before and after the addition of clarithro-mycin 400 mg/day for 6 days, and again 1 month after discontinuation of clarithromycin. The dose and duration of clarithromycin were decided according to usual clinical practice. In healthy male volunteers, mean Cmax and AUC0–10 h of cabergoline increased to a similar degree during co-administration of clarithromycin. Mean plasma cabergoline concentration over 10 h post-dosing increased 2.6-fold with clarithromycin co-administration. In PD patients, plasma cabergoline concentration increased 1.7-fold during clarithromycin co-administration. Co-administration with clarithromycin may increase the blood concentration of cabergoline in healthy volunteers and in PD patients. Keywords:: cabergoline, clarithromycin, drug-drug interaction, Parkinson’s disease |
| first_indexed | 2024-12-17T15:09:44Z |
| format | Article |
| id | doaj.art-b44ab4664fb641c8a3e52cf97dad00f4 |
| institution | Directory Open Access Journal |
| issn | 1347-8613 |
| language | English |
| last_indexed | 2024-12-17T15:09:44Z |
| publishDate | 2006-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Pharmacological Sciences |
| spelling | doaj.art-b44ab4664fb641c8a3e52cf97dad00f42022-12-21T21:43:42ZengElsevierJournal of Pharmacological Sciences1347-86132006-01-0110015964Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s DiseaseAkiko Nakatsuka0Masahiro Nagai1Hayato Yabe2Noriko Nishikawa3Takuo Nomura4Hiroyoko Moritoyo5Takashi Moritoyo6Masahiro Nomoto7Clinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Pharmacology and Therapeutics, Ehime University School of Medicine andClinical Therapeutic Research Centre, Ehime University Hospital, Shitsukawa Tohon, Ehime 791-0295, JapanClinical Pharmacology and Therapeutics, Ehime University School of Medicine and; Clinical Therapeutic Research Centre, Ehime University Hospital, Shitsukawa Tohon, Ehime 791-0295, Japan; Corresponding author. nomoto@m.ehime-u.ac.jpAbstract.: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concentration of cabergoline in healthy male volunteers and in PD patients. Study 1: Ten healthy male volunteers were enrolled and were randomized to take a single oral dose of cabergoline (1 mg/day) for 6 days or a single oral dose of cabergoline plus clarithromycin (400 mg/day) for 6 days. Study 2: Seven PD patients receiving stable cabergoline doses were enrolled. They were evaluated for the plasma cabergoline concentration before and after the addition of clarithro-mycin 400 mg/day for 6 days, and again 1 month after discontinuation of clarithromycin. The dose and duration of clarithromycin were decided according to usual clinical practice. In healthy male volunteers, mean Cmax and AUC0–10 h of cabergoline increased to a similar degree during co-administration of clarithromycin. Mean plasma cabergoline concentration over 10 h post-dosing increased 2.6-fold with clarithromycin co-administration. In PD patients, plasma cabergoline concentration increased 1.7-fold during clarithromycin co-administration. Co-administration with clarithromycin may increase the blood concentration of cabergoline in healthy volunteers and in PD patients. Keywords:: cabergoline, clarithromycin, drug-drug interaction, Parkinson’s diseasehttp://www.sciencedirect.com/science/article/pii/S1347861319345396 |
| spellingShingle | Akiko Nakatsuka Masahiro Nagai Hayato Yabe Noriko Nishikawa Takuo Nomura Hiroyoko Moritoyo Takashi Moritoyo Masahiro Nomoto Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease Journal of Pharmacological Sciences |
| title | Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease |
| title_full | Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease |
| title_fullStr | Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease |
| title_full_unstemmed | Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease |
| title_short | Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson’s Disease |
| title_sort | effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with parkinson s disease |
| url | http://www.sciencedirect.com/science/article/pii/S1347861319345396 |
| work_keys_str_mv | AT akikonakatsuka effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT masahironagai effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT hayatoyabe effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT norikonishikawa effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT takuonomura effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT hiroyokomoritoyo effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT takashimoritoyo effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease AT masahironomoto effectofclarithromycinonthepharmacokineticsofcabergolineinhealthycontrolsandinpatientswithparkinsonsdisease |